ENGLOBAL CORP by ENGlobal Corp. Azioni (OTC: ENGCQ)

Ultime notizie per ENGLOBAL CORP by ENGlobal Corp. (OTC:ENGCQ) Azioni

ENGLOBAL CORP by ENGlobal Corp.

Earnings

News

INDP

Indaptus Therapeutics FY24 EPS $(1.61) Up From $($1.83) YoY

Biotech

General

RNAZ

TransCode Therapeutics Announces Safety Review Committee Approval To Open A Fourth Cohort Of Its Phase I/II Clinical Trial Of TTX-MC138

Rosenblatt analyst Barton Crockett maintains Emerald Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) with a Buy and maintains $7.8 price target.

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Emerald Holding, Maintains $7.8 Price Target

Earnings Beats

TRML

Tourmaline Bio Q4 2024 GAAP EPS $(0.86) Beats $(0.88) Estimate, Cash Balance Of $294.9M As Of December 31, Providing Expected Runway Into The Second Half Of 2027

Guidance

GIII

G-III Apparel Sees FY26 Net Sales Of $3.14B Vs. $3.23B Estimate, Adjusted EPS Is Expected Between $4.15-$4.25 Vs. $4.10 Estimate

BLDP

Ballard Expects Revenue In 2025 To Be Back-half Weighted

Rosenblatt analyst Kevin Cassidy maintains Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) with a Buy and maintains $5 price target.

NVTS

Rosenblatt Maintains Buy on Navitas Semiconductor, Maintains $5 Price Target

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan.
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech's board and management have determined that CGM technology and related data driven insights will be the Company's primary strategic focus moving forward.&nbsp;
The successful execution of Trinity Biotech's comprehensive transformation plan is expected to drive near-term profitability improvements, creating potential opportunities to optimize its portfolio and support CGM-related growth. As part of this effort, Barclays is now actively assessing how the Company's existing businesses can best align with this new strategic direction.&nbsp;

TRIB

Trinity Biotech Taps Barclays to Drive Strategic Shift Toward Glucose Monitoring Tech

Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 110.77 percent decrease over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $48.84 million which beat the analyst consensus estimate of $47.75 million by 2.29 percent. This is a 47.09 percent decrease over sales of $92.31 million the same period last year.

ACTG

Acacia Research Q4 2024 Adj EPS $(0.07) Beats $(0.08) Estimate, Sales $48.84M Beat $47.75M Estimate

Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $24.50 million which missed the analyst consensus estimate of $30.41 million by 19.44 percent. This is a 47.65 percent decrease over sales of $46.80 million the same period last year.

Earnings Misses

Ballard Power Systems Q4 2024 GAAP EPS $(0.16) Misses $(0.12) Estimate, Sales $24.50M Miss $30.41M Estimate

Truist Securities analyst Michael Ciarmoli upgrades Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) from Hold to Buy and raises the price target from $49 to $56.

Upgrades

MRCY

Truist Securities Upgrades Mercury Sys to Buy, Raises Price Target to $56

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) has completed its <a href="https://www.benzinga.com/pressreleases/25/03/g44273105/nv5-acquires-herman-cx-strengthens-domestic-data-center-commissioning-business" target="_blank" rel="noreferrer noopener">acquisition of Herman Cx</a>, a U.S.-based provider of commissioning and conformity assessment services for hyperscale data centers. The cash-and-stock deal is expected to be immediately accretive to NV5&#8217;s earnings. Financial terms were not disclosed.
Founded in 2016, Herman Cx supports critical infrastructure for leading U.S. technology companies, financial institutions, and co-location data centers. The firm offers design reviews and functional testing to ensure data center systems meet cooling, power, and safety requirements. It has commissioned infrastructure up to 175 MW and provides end-to-end critical testing, from individual components to full system integration.
NV5 CEO Ben Heraud said the acquisition strengthens the company&#8217;s hyperscale data center commissioning capabilities and supports its growth in the domestic market. He added that mission-critical commissioning also opens cross-selling opportunities across NV5&#8217;s MEP design, fire protection, and power delivery services while generating recurring revenue beyond the initial build phases.
&#8220;Data centers continue to be a strategic growth driver for NV5, generating over 20% organic growth,&#8221; said Andrew Chang, chief operating officer of buildings and technology. &#8220;We&#8217;re excited about the cross-selling potential this acquisition brings.&#8221;
The announcement follows NV5&#8217;s recent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44216571/nv5-continues-to-strengthen-global-data-center-expansion-with-18-million-in-recent-contract-awards" rel="noreferrer noopener">award of $18 million</a> in data center design and commissioning contracts across the U.S. and Asia, further cementing its role in enabling efficient, resilient, and sustainable infrastructure for cloud and AI operations.
Price Action: NVEE shares closed lower by 2.03% to $17.41 o Wednesday.
Image via Shutterstock

NVEE

NV5 Deepens Data Center Push With Herman Cx Acquisition

Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer.

LUCD

PAVM

Lucid Diagnostics, PAVmed Reveal Positive Coverage Policy For Non-invasive Screening Of Esophageal Precancer And Cancer In New York State

Truist Securities analyst Ki Bin Kim downgrades Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Buy to Hold and lowers the price target from $114 to $105.

Downgrades

Truist Securities Downgrades Federal Realty Investment to Hold, Lowers Price Target to $105

CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) reported quarterly earnings of $0.35 per share which met the analyst consensus estimate. This is a 12.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $57.89 million which beat the analyst consensus estimate of $54.11 million by 6.99 percent. This is a 3.51 percent decrease over sales of $60.00 million the same period last year.

CION

CION Invt Q4 EPS $0.35, Inline, Sales $57.89M Beat $54.11M Estimate

DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/DOCU/earnings">closing bell, on Thursday, March 13.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at 85 cents per share, up from 76 cents per share in the year-ago period. DocuSign projects quarterly revenue of $761.64 million, compared to $712.39 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 5, 2024, DocuSign reported third-quarter revenue of $754.8 million, beating the consensus estimate of $745.26 million.
DocuSign shares rose 0.8% to close at $80.13 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/docu/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Mark Murphy upgraded the stock from Underweight to Neutral and raised the price target from $70 to $75 on March 10, 2025. This analyst has an accuracy rate of 73%.</li>
<li>JMP Securities analyst Patrick Walravens reiterated a Market Outperform rating with a price target of $124 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>HSBC analyst Stephen Bersey downgraded the stock from Hold to Reduce on Dec. 6, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Citigroup analyst Tyler Radke maintained a Buy rating and raised the price target from $87 to $113 on Dec. 6, 2024. This analyst has an accuracy rate of 66%.</li>
<li>UBS analyst Karl Keirstead maintained a Neutral rating and increased the price target from $60 to $100 on Dec. 6, 2024. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying DOCU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13042212/image-90-1024x587.png" alt="" class="wp-image-822347" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13042212/image-90-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13042212/image-90-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13042212/image-90-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13042212/image-90.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>

Markets

Trading Ideas

DOCU

Top Wall Street Forecasters Revamp DocuSign Price Expectations Ahead Of Q4 Earnings

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fspire.com%2F&amp;esheet=54223637&amp;newsitemid=20250313356433&amp;lan=en-US&amp;anchor=Spire+Global%2C+Inc.&amp;index=1&amp;md5=1dd4b2b621a840da6428892d7155811d">Spire Global, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) ("Spire" or "the Company"), a global provider of space-based data, analytics and space services, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40.0 million to the Company before deducting placement agent fees and offering expenses. The private placement is expected to close on or about March 14, 2025, subject to the satisfaction of customary closing conditions.
Pursuant to the terms of the securities purchase agreement, Spire is selling an aggregate of 5.0 million shares of its Class A common stock (or pre-funded warrants in lieu thereof) at a purchase price of $8.00 per share and $7.9999 per pre-funded warrant. Each pre-funded warrant will have an exercise price of $0.0001 per share of common stock, will be exercisable immediately and will expire when exercised in full.
Craig-Hallum Capital Group LLC acted as the sole placement agent for the private placement.
The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes.

Offerings

SPIR

Spire To Sell 5M Stock at $8 Each in Funding Round Backed by Craig-Hallum

Gold, silver and copper are expected to provide the majority of 2025 revenue.&nbsp;

RGLD

Royal Gold Expects 2025 Total Sales For Gold Of 210,000 – 230,000 oz, Silver Of 	
2.7 – 3.3 M oz

Rosenblatt analyst Catharine Trebnick maintains Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Buy and raises the price target from $10.5 to $12.

Rosenblatt Maintains Buy on Sprinklr, Raises Price Target to $12

Piper Sandler analyst James Fish maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Neutral and lowers the price target from $153 to $131.

Comments

ENGLOBAL CORP by ENGlobal Corp.

Notizie

Ultime notizie per ENGLOBAL CORP by ENGlobal Corp. (OTC:ENGCQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO